First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163 BNT163 is the first candidate from BioNTech’s infectious disease mRNA vaccine ...

Dr. Prince will provide an overview of Herpes Simplex Virus (HSV), including the distinctions between HSV-1 and HSV-2, their anatomical sites of infection, and the mechanisms underlying viral ...

Infection with the virus that’s the main cause of cold sores may double a person’s risk of developing dementia, according to a new study. Adding to growing evidence of a link between the two, further ...

Italian pharma Alfasigma has penned a 125 million euro ($145 million) deal for the rights to an injectable form of an investigational herpes simplex virus (HSV) encephalitis treatment. | Italian ...

The researchers found 25.6 million people aged 15 to 49 years had new HSV-2 infections and 519.5 million (13.3%) had existing (prevalent) HSV-2 infections globally in 2020. (HealthDay News) — The ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Some studies found herpes simplex virus 1 increased ...

– ABI-5366 is currently being evaluated in ongoing Phase 1b clinical trial with interim proof-of-concept data expected in fall 2025 – SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ...

Pritelivir demonstrated clinically meaningful and highly statistically significant superiority (p=0.0047) in lesion healing up to 28 days of treatment, compared with standard-of-care (SoC) treatments ...

Number of people with at least one episode of HSV-attributable genital ulcer disease was 187.9 and 16.7 million for HSV-2, HSV-1 in 2020. (HealthDay News) — The incidence and prevalence of genital ...